Alligator Bioscience (STO:ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumour -directed immunotherapy, on Tuesday presented preclinical data on the immune activating antibody ATOR-1015 at the American Association of Cancer Research (AACR) Annual Meeting 2018 taking place in Chicago, Illinois.

ATOR-1015 is a first-in-class bispecific tumour-directed antibody, targeting CTLA-4 and OX40, designed to selectively activate the immune system in the tumour, without increasing systemic toxicity.

Reportedly, the preclinical data demonstrated that ATOR-1015 physically localises to the tumour and selectively activates the immune system in the tumour area, confirming the intended ATOR-1015 mechanism of action.

ATOR-1015 is primarily designed for combination therapy with a PD-1 blocking antibody and the potential of this approach is supported with preclinical data reporting enhanced anti-tumour effect of ATOR-1015 in combination with an anti-PD -1 antibody, as compared to anti-PD-1 monotherapy.

In addition, ATOR-1015 demonstrated superior efficacy compared to mono-targeting CTLA-4 and OX40 antibodies.

According to the company, the results presented in Chicago confirm that its CTLA-4 bispecific antibody ATOR-1015 selectively activates the immune system in the tumour area. This offers great potential for an improved benefit/risk profile for cancer patients.

Alligator is planning to initiate an ATOR-1015 phase I study during the second half of 2018.Published: 2018-04-17 15:00:00 CEST